(2017) Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis.
(2015) What to make of cannabis and cognition in MS: In search of clarity amidst the haze.
(2015) Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
(2015) Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?
(2015) Cannabis in multiple sclerosis treatment: possibilities and limits.
(2015) The therapeutic potential of cannabinoids for movement disorders.
(2015) Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses.
(2015) Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids.
(2014) Complementary and alternative medical therapies in multiple sclerosis–the American Academy of Neurology guidelines: a commentary.
(2015) Disease modifying nutricals” for multiple sclerosis.
(2014) Medical marijuana in neurology.
(2014) Cannabinoids: new promising agents in the treatment of neurological diseases.
(2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.
(2014) Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
(2014) Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
(2013) Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.
(2012) What place for ▾ cannabis extract in MS?
(2012) Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids.
(2012) Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
(2012) Potential control of multiple sclerosis by cannabis and the endocannabinoid system.
(2012) Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
(2012) Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
(2012) The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
(2012) Cannabinoids for symptomatic therapy of multiple sclerosis.
(2011) THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
(2011) Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
(2011) Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.
(2011) Role of cannabinoids in multiple sclerosis.
(2011) The multiplicity of action of cannabinoids: implications for treating neurodegeneration.
(2010) Cannabis-based medicines in multiple sclerosis–a review of clinical studies.
(2009) Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.
(2009) Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.
(2009) Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.
(2009) Cannabidiol: a promising drug for neurodegenerative disorders?
(2009) A review of complementary and alternative medicine (CAM) by people with multiple sclerosis.
(2009) Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods.
(2008) The endocannabinoid system and multiple sclerosis.
(2008) Endocannabinoids in the retina: from marijuana to neuroprotection.
(2008) Non-conventional medicine and multiple sclerosis.
(2008) Multiple sclerosis, cannabinoids, and cognition.
(2007) Cannabinoid control of neuroinflammation related to multiple sclerosis.
(2007) Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.
(2007) Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.
(2007) Multiple sclerosis as a painful disease.
(2007) Treatment for ataxia in multiple sclerosis.
(2006) Implication of cannabinoids in neurological diseases.
(2006) Complementary and alternative medicine: is there a role in multiple sclerosis?
(2006) Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
(2006) A review of the evidence for efficacy of complementary and alternative medicines in MS.
(2005) From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases.
(2004) Endocannabinoids and their involvement in the neurovascular system.
(2005) Cannabinoids in multiple sclerosis — therapeutically reasonable?
(2005) Alternative and complementary therapies in multiple sclerosis.
(2005) The safety of cannabinoids for the treatment of multiple sclerosis.
(2005) Emerging properties of cannabinoid medicines in management of multiple sclerosis.
(2004) Towards cannabis and cannabinoid treatment of multiple sclerosis.
(2004) Marijuana and multiple sclerosis.
(2004) Cannabinoids in multiple sclerosis: do they have a therapeutic role?
(2003) Cannabis and the brain.
(2003) The therapeutic potential of cannabis in multiple sclerosis.
(2003) Therapeutic potential of cannabinoids in CNS disease.
(2002) The therapeutic potential of the cannabinoids in neuroprotection.
(2002) Cannabinoids and multiple sclerosis.
(2002) Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.
(2001) The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection.
(2000) Treatments for fatigue in multiple sclerosis: a rapid and systematic review.